Twist Bioscience (TWST) just tied its antibody characterization platform to Lilly TuneLab, an AI and machine learning drug discovery hub built around Eli Lilly research data and collaborating biotech users.
The Lilly TuneLab agreement comes after a powerful run in Twist Bioscience’s shares, with a 90 day share price return of 80.19% and year to date share price return of 408.18%, while the 1 year total shareholder return is very large at about 5x. Recent momentum has been strong, with a 7 day share price return of 19.19% and 30 day share price return of 13.06%, even though the latest session saw the share price slip 0.74% to close at US$164.60. Over longer horizons, the total shareholder return of about 7x over three years and 58.27% over five years signals that investors have already priced in a lot of optimism, so fresh partnerships like TuneLab tend to influence expectations around future opportunity and risk rather than reset the story entirely.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.